- Home
- MCB vs ABUS Comparison
MCB vs ABUS Comparison
Compare MCB & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCB
- ABUS
- Stock Information
- Founded
- MCB 1999
- ABUS N/A
- Country
- MCB United States
- ABUS United States
- Employees
- MCB N/A
- ABUS N/A
- Industry
- MCB Major Banks
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- MCB Finance
- ABUS Health Care
- Exchange
- MCB Nasdaq
- ABUS Nasdaq
- Market Cap
- MCB 666.5M
- ABUS 629.1M
- IPO Year
- MCB 2017
- ABUS N/A
- Fundamental
- Price
- MCB $60.94
- ABUS $3.20
- Analyst Decision
- MCB Buy
- ABUS Strong Buy
- Analyst Count
- MCB 4
- ABUS 4
- Target Price
- MCB $71.00
- ABUS $5.50
- AVG Volume (30 Days)
- MCB 75.0K
- ABUS 919.1K
- Earning Date
- MCB 01-23-2025
- ABUS 02-27-2025
- Dividend Yield
- MCB N/A
- ABUS N/A
- EPS Growth
- MCB 8.87
- ABUS N/A
- EPS
- MCB 5.34
- ABUS N/A
- Revenue
- MCB $258,166,000.00
- ABUS $6,742,000.00
- Revenue This Year
- MCB N/A
- ABUS N/A
- Revenue Next Year
- MCB $7.14
- ABUS N/A
- P/E Ratio
- MCB $11.42
- ABUS N/A
- Revenue Growth
- MCB 3.52
- ABUS N/A
- 52 Week Low
- MCB $32.46
- ABUS $2.27
- 52 Week High
- MCB $69.56
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- MCB 53.10
- ABUS 42.47
- Support Level
- MCB $59.46
- ABUS $3.16
- Resistance Level
- MCB $63.00
- ABUS $3.38
- Average True Range (ATR)
- MCB 1.83
- ABUS 0.15
- MACD
- MCB 0.40
- ABUS 0.01
- Stochastic Oscillator
- MCB 74.75
- ABUS 19.05
About MCB Metropolitan Bank Holding Corp.
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.